Procurement Summary
Country : Canada
Summary : Project: Tender_20078 - Rfi - Molecular Assay for the Detection of Enteric Protozoa
Deadline : 30 Sep 2024
Other Information
Notice Type : Tender
TOT Ref.No.: 107045794
Document Ref. No. : tender_20078
Competition : ICB
Financier : Self Financed
Purchaser Ownership : Public
Tender Value : Refer Document
Purchaser's Detail
Name :Login to see tender_details
Address : Login to see tender_details
Email : Login to see tender_details
Login to see detailsTender Details
The intent of this RFI is to receive feedback from the marketplace regarding a commercial Health Canada approved molecular multiplex assay for detection of Giardia duodenalis (syn. G. intestinalis, G. lamblia), Cryptosporidium spp., and Entamoeba histolytica in fecal specimens. The availability of additional targets on the same assay for other protozoan organisms such as Cyclospora, Cystoisospora, Sarcocystis, Balantioides, Dientamoeba fragilis, or Blastocystis is also of interest. Detection should be direct from clinical fecal specimens (e.g. feces or fecal swabs). Scope of Work PHO is seeking an assay to potentially partially replace or supplement current microscopy-based methods for identification of the listed organisms. PHO has no firm plans or timelines for implementation at this time, and is seeking information on available products in order to help address the availability and feasibility of the new test method as a potential replacement. PHO anticipates that, should it proceed with implementation of a new molecular assay test method, the estimated volumes would be in the region of 20, 000 to 40, 000 tests per year across PHO laboratory locations, although exact siting is not yet established.
Solicitation Type : RFI - Request for Information (Informal)
Reference Number : 00004222398
Location : Ontario
Purchase Type : Not Stated
Dates Publication : 2024/09/10 11:21:00 AM EDT
Closing Date : 2024/09/30 04:00:00 PM EDT
Contact Information : Jonathon Martynski
: jonathon.martynski@oahpp.ca
:
Description : The intent of this RFI is to receive feedback from the marketplace regarding a commercial Health Canada approved molecular multiplex assay for detection of Giardia duodenalis (syn. G. intestinalis, G. lamblia), Cryptosporidium spp., and Entamoeba histolytica in fecal specimens. The availability of additional targets on the same assay for other protozoan organisms such as Cyclospora, Cystoisospora, Sarcocystis, Balantioides, Dientamoeba fragilis, or Blastocystis is also of interest. Detection should be direct from clinical fecal specimens (e.g. feces or fecal swabs). Scope of Work PHO is seeking an assay to potentially partially replace or supplement current microscopy-based methods for identification of the listed organisms. PHO has no firm plans or timelines for implementation at this time, and is seeking information on available products in order to help address the availability and feasibility of the new test method as a potential replacement. PHO anticipates that, should it proceed with implementation of a new molecular assay test method, the estimated volumes would be in the region of 20, 000 to 40, 000 tests per year acr...
Documents
Tender Notice